Drugs / Refresh Plus
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT04393441 Background | Jun 2020 → Jun 2021 | dry eye syndrome | Allergan | Completed | No outcome recorded |
| Phase 3 | NCT01105221 Comparator | Apr → Nov 2010 | dry eye syndrome | Korea Institute of Oriental Medicine | Completed | No outcome recorded |
| Phase 4 | NCT06294015 Comparator | Mar 2024 → Dec 2025 | dry eye syndrome, glaucoma | University of Sherbrooke | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Refresh Plus | “On top of this intervention is standard artificial tears therapy (Refresh Plus), applied four times daily.” NCT06294015 ↗ |
| Known as | Sodium carboxymethylcellulose | “Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose).” NCT01105221 ↗ |
| Route | Topical | “Topical eye drops” NCT04393441 ↗ |